Cannara Historical Cash Flow
| LOVE Stock | CAD 0.78 0.08 11.43% |
Analysis of Cannara Biotech cash flow over time is an excellent tool to project Cannara Biotech future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Dividends Paid of 0.0 or Capital Expenditures of 15.4 M as it is a great indicator of Cannara Biotech ability to facilitate future growth, repay debt on time or pay out dividends.
Financial Statement Analysis is much more than just reviewing and examining Cannara Biotech latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Cannara Biotech is a good buy for the upcoming year.
Cannara |
About Cannara Cash Flow Analysis
The Cash Flow Statement is a financial statement that shows how changes in Cannara balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Cannara's non-liquid assets can be easily converted into cash.
Cannara Biotech Cash Flow Chart
Add Fundamental
Capital Expenditures
Capital Expenditures are funds used by Cannara Biotech to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Cannara Biotech operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.Stock Based Compensation
Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.Most accounts from Cannara Biotech's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Cannara Biotech current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Cannara Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. At this time, Cannara Biotech's Net Borrowings is fairly stable compared to the past year. Depreciation is likely to climb to about 6 M in 2024, whereas Investments are likely to drop (11.4 M) in 2024.
| 2021 | 2023 | 2024 (projected) | Stock Based Compensation | 349.5K | 1.6M | 865.0K | Change To Liabilities | 2.4M | 2.8M | 2.0M |
Cannara Biotech cash flow statement Correlations
Click cells to compare fundamentals
Cannara Biotech Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Cannara Biotech cash flow statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change To Inventory | (2.5M) | (3.4M) | (8.2M) | (8.3M) | (7.5M) | (7.1M) | |
| Investments | (8.6M) | (30.8M) | (15.3M) | (9.5M) | (10.9M) | (11.4M) | |
| Change In Cash | (18.7M) | 388.1K | 4.0M | (7.8M) | (7.0M) | (6.6M) | |
| Net Borrowings | (235.5K) | (562.7K) | 10.1M | 27.6M | 31.7M | 33.3M | |
| Free Cash Flow | (18.1M) | (33.2M) | (21.5M) | (4.4M) | (5.1M) | (5.4M) | |
| Change In Working Capital | (289.6K) | (3.8M) | (11.5M) | (6.1M) | (5.5M) | (5.8M) | |
| Begin Period Cash Flow | 26.5M | 7.8M | 8.2M | 12.1M | 13.9M | 12.4M | |
| Total Cashflows From Investing Activities | (21.6M) | (8.6M) | (30.8M) | (15.3M) | (17.6M) | (18.5M) | |
| Other Cashflows From Financing Activities | 3.3M | (1.1M) | (1.5M) | (2.2M) | (1.9M) | (1.9M) | |
| Depreciation | 2.4M | 2.9M | 3.9M | 4.9M | 5.7M | 6.0M | |
| Other Non Cash Items | 1.1M | (169.2K) | (659.0K) | (2.2M) | (2.0M) | (1.9M) | |
| Capital Expenditures | 9.2M | 30.6M | 15.1M | 9.9M | 8.9M | 15.4M | |
| Total Cash From Operating Activities | (9.3M) | (2.1M) | (6.1M) | 5.4M | 6.3M | 6.6M | |
| Change To Account Receivables | 28.7K | (2.8M) | (5.7M) | (2.0M) | (1.8M) | (1.9M) | |
| Change To Operating Activities | (658.5K) | 253.0K | (274.1K) | 23.5K | 27.0K | 28.3K | |
| Net Income | (12.5M) | (1.5M) | 2.3M | 6.9M | 8.0M | 8.4M | |
| Total Cash From Financing Activities | (914.8K) | 33.3M | 25.5M | (3.7M) | (3.3M) | (3.2M) | |
| End Period Cash Flow | 7.8M | 8.2M | 12.1M | 4.3M | 3.8M | 3.7M | |
| Change To Netincome | 4.1M | 1.7M | 189.3K | (937.6K) | (843.9K) | (801.7K) | |
| Change To Liabilities | 938.2K | 1.1M | 2.6M | 2.4M | 2.8M | 2.0M | |
| Stock Based Compensation | 782.1K | 331.6K | 349.5K | 1.8M | 1.6M | 865.0K |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Cannara Stock Analysis
When running Cannara Biotech's price analysis, check to measure Cannara Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cannara Biotech is operating at the current time. Most of Cannara Biotech's value examination focuses on studying past and present price action to predict the probability of Cannara Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cannara Biotech's price. Additionally, you may evaluate how the addition of Cannara Biotech to your portfolios can decrease your overall portfolio volatility.